Dr. Lancet on CPX-351 in Elderly Patients With AML | OncLive

Dr. Lancet on CPX-351 in Elderly Patients With AML

July 28, 2016

Jeffrey E. Lancet, MD, medical oncologist, Moffitt Cancer Center, discusses results of a randomized phase III study comparing the efficacy of CPX-351 (Vyxeos) versus daunorubicin (7+3) plus cytarabine in older patients with newly diagnosed, high-risk acute myeloid leukemia (AML).

Jeffrey E. Lancet, MD, medical oncologist, Moffitt Cancer Center, discusses results of a randomized phase III study comparing the efficacy of CPX-351 (Vyxeos) versus daunorubicin (7+3) plus cytarabine in older patients with newly diagnosed, high-risk acute myeloid leukemia (AML).

Patients with a history of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, therapy-related AML, or AML with MDS-related cytogenetics were eligible to enroll in the trial, Lancet explains.

Results of the study showed that there was a 3.5-month improvement in overall survival associated with CPX-351, he says. Additionally, CPX-351 led to a 31% reduction in the risk of death. These findings are very encouraging as it shows a benefit with an agent that is not the standard of care.


x